Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$262K Buy
1,056
+17
+2% +$3.66K 0.12% 190
2026
Q1
$207K Sell
1,039
-9
-0.9% -$2K 0.1% 211
2025
Q4
$239K Sell
1,048
-257
-20% -$58.5K 0.12% 180
2025
Q3
$302K Sell
1,305
-12
-0.9% -$2.44K 0.15% 143
2025
Q2
$254K Sell
1,317
-109
-8% -$20.3K 0.14% 165
2025
Q1
$299K Sell
1,426
-34
-2% -$6.61K 0.18% 128
2024
Q4
$249K Buy
1,460
+273
+23% +$50.2K 0.14% 149
2024
Q3
$235K Buy
+1,187
New +$222K 0.14% 134
2023
Q1
Sell
-1,295
Closed -$209K 145
2022
Q4
$209K Buy
+1,295
New +$199K 0.19% 124
2022
Q3
Sell
-1,391
Closed -$213K 133
2022
Q2
$213K Sell
1,391
-11
-0.8% -$1.68K 0.18% 120
2022
Q1
$227K Buy
+1,402
New +$204K 0.16% 133
2021
Q3
Sell
-3,695
Closed -$432K 156
2021
Q2
$432K Buy
3,695
+223
+6% +$25.1K 0.32% 92
2021
Q1
$373K Sell
3,472
-97
-3% -$10.4K 0.28% 103
2020
Q4
$382K Buy
3,569
+27
+0.8% +$2.6K 0.32% 96
2020
Q3
$310K Buy
3,542
+3
+0.1% +$282 0.32% 96
2020
Q2
$347K Sell
3,539
-346
-9% -$30.5K 0.37% 89
2020
Q1
$296K Sell
3,885
-1,297
-25% -$110K 0.35% 83
2019
Q4
$458K Buy
+5,182
New +$430K 0.44% 72

Other funds holding ABBV

Capital Square's ABBV Position: Q2 2026 in Review

Capital Square increased its AbbVie (ABBV) stake by 1.6% in Q2 2026, buying an estimated $3.66K and bringing the position to 1,056 shares worth $262K. The position accounts for 0.12% of the portfolio, ranked #190.

Capital Square first reported a position in ABBV in Q4 2019 and has held it in 18 quarters since. The position peaked at $458K in Q4 2019. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Capital Square held 1,056 shares of AbbVie worth $262K as of Q2 2026.
  • Capital Square bought 17 AbbVie shares in Q2 2026, an estimated $3.66K.
  • AbbVie made up 0.12% of Capital Square's portfolio in Q2 2026, its #190 holding.
  • Capital Square first reported a position in AbbVie in Q4 2019 and has held it in 18 quarters since.
  • Capital Square's AbbVie position peaked at $458K in Q4 2019.
  • 4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Capital Square's 13F filing for Q2 2026, filed 13 Aug 2026.